Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663173 | 0.83 | LOXL2 (0.60) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL18291844 | 0.83 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL7169246 | 0.82 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL28338445 | 0.82 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL401081 | 0.82 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL31059889 | 0.82 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL29403791 | 0.82 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL28335219 | 0.80 | LOXL2 (0.67) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL4958614 | 0.79 | LOXL2 (0.60) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL2385292 | 0.78 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1BHRH3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6355615-B1 | CYCLIC POLYAMIDEESTER COPOLYMERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-12 | — | — | US | claimed |
| EP-0986549-A1 | DESOXYCYCLODEPSIPEPTIDES AND THEIR USE FOR COMBATTING ENDOPARASITES | Bayer Aktiengesellschaft (DE) | 2000-03-22 | — | — | EP | claimed |
| WO-1998055469-A1 | DESOXYCYCLODEPSIPEPTIDES AND THEIR USE FOR COMBATTING ENDOPARASITES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-10 | — | — | WO | claimed |
| EP-4317160-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117098759-A | Heterocyclic compounds and their use | 组合化学工业株式会社 | 2023-11-21 | — | — | CN | disclosed |
| CN-116354931-A | Substituted oxazole derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115093408-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-09-23 | — | — | CN | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | SHIONOGI & CO., LTD. (JP) | 2022-07-28 | — | — | US | disclosed |
| WO-2022119899-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN | SHIONOGI & CO., LTD. (JP) | 2022-06-09 | — | — | WO | disclosed |
| CN-114401965-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6355615-B1 | CYCLIC POLYAMIDEESTER COPOLYMERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-12 | — | — | US | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0986549-A1 | DESOXYCYCLODEPSIPEPTIDES AND THEIR USE FOR COMBATTING ENDOPARASITES | Bayer Aktiengesellschaft (DE) | 2000-03-22 | — | — | EP | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998055469-A1 | DESOXYCYCLODEPSIPEPTIDES AND THEIR USE FOR COMBATTING ENDOPARASITES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-10 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | CYC1, MT-CO1, ABCB11 | LOXL2 4816/4885MTNR1A 1154/4885MTNR1B 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.